Fluvastatin in the Therapy of Acute Coronary Syndrome
This study is to evaluate the safety and efficacy of fluvastatin versus placebo, dosed shortly after or immediately when the coronary event occurs...
Brief Summary
Official Title: “Fluvastatin in the Therapy of Acute Coronary Syndrome”
This study is to evaluate the safety and efficacy of fluvastatin versus placebo, dosed shortly after or immediately when the coronary event occurs.
- Study Type: Interventional
- Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
- Study Primary Completion Date: February 2007
Intervention(s) in this Clinical Trial
- Drug: Fluvastatin
Outcome Measures for this Clinical Trial
Primary Measures
- Change from baseline in circulating markers of inflammation after 4 weeks and after 52 weeks
Secondary Measures
- Occurrence of death, nonfatal myocardial infarction, cardiac arrest with resuscitation, recurrent symptomatic ischemia, and urgent revascularization after 4 weeks and after 52 weeks
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Acute coronary syndrome
- Adults, 18 years and older
Exclusion Criteria:
- History of lipid lowering therapy less than 30 days before index event
- Pregnancy and nursing
- Subject younger than 18 years
- Other inclusion and exclusion criteria may apply.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 75 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: Novartis Industry
Overall Clinical Trial Officials and Contacts
Novartis Pharmaceuticals Study Director Novartis Pharmaceuticals
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00171275
Study ID Number: CXUO320BCZ01
ClinicalTrials.gov Identifier: NCT00171275
Health Authority: Czech Republic: State Institute for Drug Control
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00171275
